B
ALXN

Bailard’s Alexion Pharmaceuticals ALXN Stock Holding History

Bailard’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-2,000
Closed -$223K – 552
2018
Q1 		$223K Sell
2,000
-200
-9% -$23.9K 0.01% 450
2017
Q4 		$263K Buy
+2,200
New +$268K 0.02% 393
2016
Q1 		– Sell
-2,000
Closed -$382K – 373
2015
Q4 		$382K Buy
+2,000
New +$349K 0.17% 152

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Bailard's ALXN Position: Q2 2018 in Review

Bailard sold out of Alexion Pharmaceuticals (ALXN) in Q2 2018, closing a stake of 2,000 shares — an estimated $223K sold.

Bailard first reported a position in ALXN in Q4 2015 and held it in 3 quarters. The position peaked at $382K in Q4 2015. 600 funds tracked by Wall St. Rank hold ALXN as of Q2 2018.

  • Bailard reported no remaining Alexion Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Bailard sold 2,000 Alexion Pharmaceuticals shares in Q2 2018, an estimated $223K.
  • Bailard first reported a position in Alexion Pharmaceuticals in Q4 2015 and held it in 3 quarters.
  • Bailard's Alexion Pharmaceuticals position peaked at $382K in Q4 2015.
  • 600 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2018.

Based on Bailard's 13F filing for Q2 2018, filed 8 Aug 2018.